Akari Therapeutics (AKTX) vs Psyence Biomedical (PBM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Akari Therapeutics (AKTX) has outperformed Psyence Biomedical (PBM) over the past year, losing 78.5% versus a loss of 97.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTX | PBM |
|---|---|---|
| Share price | $8.77 | $4.97 |
| Market cap | $20.04M | — |
| 1-day change | +3.30% | -2.93% |
| YTD return | -24.13% | -82.59% |
| 1-year return | -78.50% | -97.05% |
| 5-year return | -99.34% | — |
| EPS (TTM) | $0.00 | $-12.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.00 | $150.78 |
| 52-week low | $3.02 | $1.92 |
| Distance from 52-week high | -78.08% | -96.70% |
| Analyst consensus | none | — |
| Avg. price target upside | +190.76% | — |
| Average volume | 61.08K | 94.85K |
| Shares outstanding | 2.29M | — |
| Employees | 5 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AKTX has outperformed PBM by 18.5 percentage points over the past year.
About Akari Therapeutics
AKTX stock →Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
AKTX vs PBM FAQ
Which stock has performed better over the past year, AKTX or PBM?
AKTX returned -78.50% over the past 12 months, compared with -97.05% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are Akari Therapeutics and Psyence Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.